Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells

PLoS ONE - United States
doi 10.1371/journal.pone.0151585
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Erratum To: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Cardiology and Therapy
2016English

Exploring Novel Pharmacotherapeutic Applications and Repurposing Potential of Sodium Glucose CoTransporter 2 (SGLT2) Inhibitors

Clinical and Experimental Pharmacology and Physiology
PhysiologyPharmacology
2018English

Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View

2020English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Increased Grip Strength With Sodium-Glucose Cotransporter 2

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2016English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
2019English

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Drug Metabolism and Pharmacokinetics
PharmacologyPharmaceutical Science
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy